Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KC1036 + Toripalimab + Chemotherapy in Advanced ESCC
NCT07481058Phase 2Recruiting
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of connitinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Beijing Konruns Pharmaceutical Co., Ltd.. Started Dec 2025; status: recruiting.
02
Drugs
connitinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07481058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07481058.